Please login to the form below
morphosys
This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
Daily brief: Novartis spends big on ezcema,
Novartis eczema deal worth up to $1bn for biotechs. MorphoSys and Galapagos have signed a major new deal with Novartis on their atopic dermatitis candidate MOR106, an IL-17c antibody. ... The deal adds to MorphoSys’momentum, as it launched its listing
Latest news
-
Roche starts new late-stage trials of Alzheimer’s candidate
In the interim, Roche and partner MorphoSys - which applied its antibody-generating technology to the creation of the drug - have been carrying out safety studies to ensure that hiking exposure to ... 2020. The decision to press ahead with the phase III
-
Janssen’s Tremfya cleared for European use
Tremfya, an anti-IL-23 monoclonal antibody, was developed using MorphoSys ’HuCAL antibody library technology, allowing the German biotech to collect royalties on Tremfya sales under a multiple target deal it ... Dr Simon Moroney, chief executive officer
-
Lilly and Boehringer combine breast cancer drugs in trial
BI 836845 is one of the drugs that has emerged from the company's long-standing antibody collaboration with MorphoSys, and is also being tested in combination with Novartis' Femara (exemestane)
-
Pfizer signs high-level deal with GPCR specialist Heptares
It also has collaborations in place with AstraZeneca (AZ), Merck &Co's Cubist unit, MorphoSys and Takeda.
-
Amgen decision on brodalumab unsettles anti-IL-17 class
J/Morphosys.
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Deal Watch November 2016
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
-
Pharma deals in March 2015
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during August 2014
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
-
Pharma deals during June 2014
Joining the checkpoint modulator fray, Merck Serono formed a partnership with Morphosys to discover and develop antibodies against certain immune checkpoints using the Morphosys Ylanthia platform.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
Industry round up: appointments
Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Dave Lemus joins Proteros as an executive board member
He has also held roles with MorphoSys and Hoffman La Roche.
-
MorphoSys appoints Dr Markus Enzelberger as CSO
MorphoSys appoints Dr Markus Enzelberger as CSO. He succeeds Dr Marlies Sproll who resigns. ... German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.
-
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team. She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
Featured jobs
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Business Unit Head, Medical Communications, London
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
- Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
- AstraZeneca joins Merck in Brexit stockpiling effort
- Vyriad inks immunotherapy alliance with Merck/Pfizer
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
